Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Joel Bernstein to remain at Winston Pharmaceuticals

This article was originally published in Scrip

Executive Summary

Winston Pharmaceuticals (US) has announced that Dr Joel Bernstein, founder of the company's wholly owned subsidiary Winston Laboratories, has rescinded his resignation as president and chief executive officer and will now continue to serve in the positions for the duration of the term set forth in his employment agreement. Dr Jeffrey Bernstein, who had previously been announced by the company's board of directors as a successor to Dr Joel Bernstein effective September 22nd (, July 30th, 2009), has withdrawn as a candidate for the positions. Winston's board reconfirmed that Robert Yolles, a member of the company's board since 2008, will succeed Dr Joel Bernstein as chairman on September 22nd.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts